VivoSeq
Infectious Disease

Chickenpox

19

Pipeline Programs↗

4

Active Trials↗

6

Companies Involved↗

Chickenpox is an emerging landscape with 19 programs across 6 companies. The most active players are Merck & Co., Novartis, GSK. 1 therapy is approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Merck & Co. logo

Merck & Co.

3 programs

Phase 3Novartis logo

Novartis

1 program

Phase 3GSK logo

GSK

13 programs

Phase 3Sanofi logo

Sanofi

3 programs

Phase 3G

Glaxo Dba Glaxosmithkline

1 program

PreclinicalAstraZeneca logo

AstraZeneca

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

14programs
Vaccine857%
Small molecule643%

Modality classified for 100% of 23 pipeline programs.

Analysis

Trial Status

17

clinical trials

Completed13 · 76%
Recruiting4 · 24%

Clinical Trials

Trial Activity

17 trials

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age
Recruiting·GSK logoGSK·Phase 3·NCT06693895·750 enrolled
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age
Recruiting·GSK logoGSK·Phase 3·NCT06740630·1,840 enrolled
A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age
Recruiting·GSK logoGSK·Phase 3·NCT06855160·900 enrolled
A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age
Recruiting·GSK logoGSK·Phase 3·NCT06806137·600 enrolled
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
Completed·GSK logoGSK·Phase 2·NCT05630846·801 enrolled
Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox
Completed·GSK logoGSK·Phase 3·NCT00226499·5,803 enrolled
Training Study to Characterize Biomarkers to Chickenpox and Yellow Fever Vaccines
Completed·UUniversity of Surrey·N/A·NCT01765413·48 enrolled
Use of a Varicella-Zoster Virus (VZV) Vaccine to Prevent Shingles in HIV-Infected Children Who Have Already Had Chickenpox
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001125·60 enrolled
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Completed·GSK logoGSK·Phase 3·NCT00127023·944 enrolled
A Study of an Investigational Zoster Vaccine in Subjects With a History of Varicella (Chickenpox) Given Concomitantly With Another Vaccine (V211-011)
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00231816·763 enrolled
Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Completed·GSK logoGSK·Phase 4·NCT00126997·1,439 enrolled
A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age
Completed·GSK logoGSK·Phase 2·NCT05084508·800 enrolled
Special Drug Use Investigation for VALTREX (Valaciclovir) (Pediatrics Chickenpox)
Completed·GSK logoGSK·N/A·NCT01390857·379 enrolled
Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases
Completed·GSK logoGSK·Phase 3·NCT00127010
A Study of the Safety and Effectiveness of a Chickenpox Vaccine in HIV-Infected Children
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000837·127 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)